NasdaqGS - Delayed Quote • USD
Scholar Rock Holding Corporation (SRRK)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 4:04 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.61 | -0.61 | -2.38 | -2.12 |
| Low Estimate | -0.72 | -0.71 | -2.6 | -2.69 |
| High Estimate | -0.57 | -0.53 | -2.07 | -0.95 |
| Year Ago EPS | -0.47 | -0.53 | -1.99 | -2.38 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 9 |
| Avg. Estimate | -- | -- | -- | 28.81M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 90M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.55 | -0.52 | -0.49 | -0.51 |
| EPS Actual | -0.47 | -0.53 | -0.5 | -0.59 |
| Difference | 0.08 | -0.01 | -0.01 | -0.08 |
| Surprise % | 14.50% | -1.90% | -2.00% | -15.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.61 | -0.61 | -2.38 | -2.12 |
| 7 Days Ago | -0.61 | -0.61 | -2.38 | -2.12 |
| 30 Days Ago | -0.56 | -0.56 | -2.23 | -2.07 |
| 60 Days Ago | -0.51 | -0.52 | -2.06 | -1.93 |
| 90 Days Ago | -0.48 | -0.5 | -1.91 | -1.68 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SRRK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -29.80% | -- | -- | 9.10% |
| Next Qtr. | -15.10% | -- | -- | 11.50% |
| Current Year | -19.60% | -- | -- | 5.70% |
| Next Year | 10.90% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/4/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Reiterates | Truist Securities: Buy to Buy | 4/3/2024 |
| Initiated | Raymond James: Strong Buy | 3/28/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/26/2024 |
Related Tickers
REPL Replimune Group, Inc.
7.90
+11.11%
FDMT 4D Molecular Therapeutics, Inc.
22.72
+0.66%
DYN Dyne Therapeutics, Inc.
30.94
-4.83%
KYMR Kymera Therapeutics, Inc.
32.96
+0.27%
CGEM Cullinan Therapeutics, Inc.
22.40
-0.62%
PLRX Pliant Therapeutics, Inc.
11.15
-3.38%
YMAB Y-mAbs Therapeutics, Inc.
11.98
-2.68%
INZY Inozyme Pharma, Inc.
4.6300
-3.74%
ORIC ORIC Pharmaceuticals, Inc.
8.83
-1.12%
KROS Keros Therapeutics, Inc.
48.69
0.00%